Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

UroGen Pharma Ltd. Director's Dealing 2020

Sep 10, 2020

32312_dirs_2020-09-10_405d2c03-a4a0-40dd-8bb4-574f5577dd37.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-08-31

Reporting Person: Smith Jason Drew (General Counsel)

More from UroGen Pharma Ltd.

Interim / Quarterly Report 2026
May 6
Regulatory Filings 2026
May 6
Proxy Solicitation & Information Statement 2026
Apr 30
Annual Report 2026
Mar 2
Regulatory Filings 2026
Mar 2
Regulatory Filings 2026
Mar 2
Director's Dealing 2026
Feb 27
Director's Dealing 2026
Feb 19
Director's Dealing 2026
Feb 11
Director's Dealing 2026
Feb 4
View all filings →